Evidence map›Paper›PMID 40349965›Full record

Trial reportAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2025

Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial.

Edmund Huang, Noriko Ammerman, Ashley Vo, Jean Hou, Sanjeev Kumar, Nicole Badash, Ben Falk, Kathleen Hernando, Matthew Gillespie, Irene K Kim and 11 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Therapeutic Potential of C1-Inhibitor in Vascular Diseases and Beyond.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  2. Exosome-primed T cell immunity is facilitated by complement activation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Edmund HuangDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Noriko AmmermanDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Ashley VoDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jean HouDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Sanjeev KumarDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Nicole BadashDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Ben FalkDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Kathleen HernandoDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Matthew GillespieDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Irene K KimDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Kathlyn LimDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Reiad NajjarDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Alice PengDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Bongha ShinDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Justin A SteggerdaDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Tsuyoshi TodoDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Todd V BrennanDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Georgios VoidonikolasDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Steven A WiselDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Peter S HeegerDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Stanley C JordanDepartments of Medicine and Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: stan.jordan@cshs.org.

Funding

Intra-graft C1 esterase inhibitor therapy for deceased kidney transplantationU01AI184203 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI Peter Scott Heeger, Stanley Clark JORDAN · 2025 to 2026
$4.4M
Intra-graft C1 esterase inhibitor therapy for deceased kidney transplantationR01AI184203 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI HEEGER, PETER SCOTT, JORDAN, STAN · 2024 to 2024
$2.2M
NIAID NIH HHS R01 AI184203NIAID NIH HHS U01 AI184203
6 · The paper itself

Abstract

Ischemia-reperfusion injury commonly causes delayed graft function (DGF) after kidney transplantation and is associated with poorer graft function and lower allograft survival. Activation of the lectin complement pathway is one mediator of ischemia-reperfusion injury. In this randomized double-blind placebo-controlled pilot study, we tested whether preimplantation intragraft administration of C1 esterase inhibitor (C1INH, a lectin/classical pathway inhibitor) into deceased donor organs improves graft function and/or reduces DGF. Forty patients were randomized 1:1 to receive allografts treated with 500 units C1INH or placebo (normal saline) into the transplant renal artery during back-table preparation. We observed no effect on DGF, but recipients of C1INH-treated allografts showed higher estimated glomerular filtration rate than recipients of placebo at 6 months (C1INH median: 55 mL/min/1.73 m

Indexed as

Complement C1 Inhibitor ProteinDelayed Graft FunctionGraft RejectionGraft SurvivalKidney Failure, ChronicKidney TransplantationReperfusion InjuryAdultAllograftsCadaverDouble-Blind MethodFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidney Function TestsComplement C1 Inhibitor Proteincomplement systemdeceased donor kidney transplantdelayed graft functionischemia-reperfusion injuryrandomized controlled trial

Identifiers

PMID40349965
PMCPMC12353822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.